Subsequently, we investigated this correlation of immunophenoscore in the TCGA-PAAD cohort and found that risk groups in IPS- PD1 and IPS-PD1-CTLA4 blocker scores had no significant difference in immunophenoscore. This evidence concerns the gene CTLA4 and pancreatic adenocarcinoma.